Background: A major limiting factor in human cancer chemotherapy is toxicity in normal tissues. Our goal was to determine whether normal proliferating cells could be protected from chemotherapeutic agents by taking advantage of the differential drug sensitivity of cell cycle G 1 checkpoint in normal and cancer cells. Methods: Normal mammary epithelial cells and mammary cancer cells were initially treated with staurosporine at a cytostatic (i.e., nonlethal) concentration, which preferentially arrests normal cells in the G 0 /G 1 phase of the cell cycle without affecting the proliferation of tumor cells. After the selective arrest of normal cells in G 0 / G 1 , both normal and tumor cells were treated with doxorubicin or camptothecin, two cytotoxic (i.e., lethal) chemotherapeutic agents. Cells were then allowed to recover in drug-free medium for 12 days. Results: After pretreatment of both normal and tumor cells with staurosporine followed by treatment with doxorubicin or camptothecin, tumor cells were selectively killed by chemotherapeutic agents, whereas normal cells resumed proliferation after the drugs were removed. Pretreatment with staurosporine also protected normal circulating lymphocytes that had been induced to proliferate in vitro with phytohemagglutinin from chemotherapeutic agents. Staurosporine-induced arrest of normal cells in G 0 /G 1 phase was reversible, and arrested cells tolerated doses of camptothecin that were more than 100-fold higher than necessary to eradicate all tumor cells in culture. Staurosporine-mediated G 0 /G 1 arrest targets the retinoblastoma protein (pRb) pathway and was accompanied by a rapid decrease in cyclin-dependent kinase (CDK) 4 protein levels, increased binding of CDK inhibitors p21 and p27 to CDK2, and inhibition of CDK2 activity in normal cells. Conclusions: Breast cancer cells with defective checkpoints regulated by the pRb pathway can be targeted specifically with chemotherapeutic agents, following staurosporine-mediated, selective and reversible G 0 /G 1 arrest in normal
Treatment of cancer with chemotherapy and radiation therapy has severe toxic side effects that damage healthy proliferating cells, such as hematopoietic precursors, hair follicle cells, and the epithelial lining of the intestine. These side effects often limit the doses of chemotherapy administered and allow tumor cells to escape treatment and to develop drug resistance. Because cancer therapy targets proliferating cells and tissues, all cells (whether normal or malignant) that proliferate are affected. If the proliferation of normal dividing cells in the body could be reversibly stopped, perhaps some toxic effects of chemotherapy would be diminished (1) (2) (3) (4) (5) .
Herein, we describe a novel therapeutic strategy that selectively targets cancer cells but ignores normal proliferating cells.
This strategy is based on the genotypic differences between normal and tumor cells that govern cell cycle regulation (6) . Unlike normal cells, which are tightly controlled by the regulation of cell cycle checkpoints, tumor cells have deregulated cell cycles, which are responsible for their continued and unabated proliferation (7) . We take advantage of this difference in cell cycle regulation between normal and tumor cells by maintaining the normal cells in a state of reversible G 0 /G 1 arrest while selectively killing the tumor cells with cytotoxic chemotherapeutic agents.
To explore the feasibility of cellular protection through reversible cell cycle arrest, we targeted the retinoblastoma protein (pRb) pathway, which governs the transition from G 0 /G 1 to S phase (8) . pRb is a major tumor suppressor that is frequently inactivated in human cancers, and alterations in pRb are linked to poor prognosis, tumor progression, and decreased sensitivity to chemotherapeutic agents (9) (10) (11) (12) (13) . Hypophosphorylated pRb serves as a tumor suppressor by binding to and inhibiting the activity of the transcription factor E2F-DP. E2F activity is required for the transactivation of many genes essential for DNA replication and is necessary for the cells to progress from G 0 /G 1 to S phase (8, (14) (15) (16) . Sequential phosphorylation of pRb throughout the cell cycle by different cyclin/cyclin-dependent kinase (CDK) complexes leads to dissociation of the pRb-E2F complexes and allows free E2F to transactivate genes that promote entry into S phase. Several studies (4, 10, 17) have provided evidence that mutations in the RB gene itself or in genes whose products influence the phosphorylation state of pRb (i.e., cyclin D1, CDK4, CDK6, or E2F) functionally inactivate pRb and contribute to tumor progression. The protection strategy described in this article allows us to take advantage of the deregulated pRb pathway in tumor cells to protect normal cells against the toxic effects of chemotherapeutic agents. Thus, we examine whether the G 0 /G 1 checkpoint pathway in normal cells can be targeted effectively to protect them from the toxic effects of chemotherapeutic agents.
MATERIALS AND METHODS

Materials, Cell Lines, and Culture Conditions
Olomoucine and roscovitine were provided by Dr. Laurent Meijer (Centre National de la Recherche Scientifique, Bretagne, France). Flavopiridol was provided by the National Cancer Institute (Bethesda, MD). Staurosporine was purchased from Boehringer Mannheim GmbH (Mannheim, Germany). MTT [i.e., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], camptothecin, and doxorubicin were from Sigma Chemical Co. (St. Louis, MO). Serum was from HyClone Laboratories, Inc. (Logan, UT), and cell culture medium was from Life Technologies, Inc. [GIBCO BRL], Rockville, MD. All other chemicals used were reagent grade. The culture conditions for 76N, 81N, and 70N normal cell strains, the MCF-10A immortalized cell line, and MCF-7, ZR75T, MDA-MB-157, Hs578T, T47D, and MDA-MB-436 breast cancer cell lines were described previously (18, 19) . The 76NE6 and 76NE7 cell lines (gifts from Dr. V. Band, Tufts Medical Institute, Boston, MA) were immortalized and cultured as described previously (20, 21) . All cells were cultured and treated at 37°C in a humidified incubator containing 6.5% CO 2 −93.5% air and were maintained free of Mycoplasma, as determined by Hoechst staining (22) .
MTT Assay
For the MTT assay, the cells were plated at 2500 cells per well in a 96-well tissue culture plate and allowed to recover for 24 hours in a humidified 6.5% CO 2 −93.5% air incubator before drug treatment. The cells were treated with the indicated concentrations of olomoucine, roscovitine, flavopiridol, or staurosporine for 48 hours and were subjected to the MTT survival assay as described previously (23) . Each data point is the average of six determinations, and the MTT assay for each experimental condition was performed at least three times.
All protection and maximum-tolerated-dose experiments were performed on cultures in 96-well plates as described above. For protection experiments, both normal and tumor cells were initially treated with 0.5 nM staurosporine for 48 hours. Next, the medium was removed, and fresh medium containing 0.5 M camptothecin or 0.125 M doxorubicin was added to the cells for 24 hours, after which the medium was replaced with drug-free medium, and the cells were allowed to recover for 12 days. Medium was replaced every other day during the recovery period. For maximum-tolerated-dose experiments, the cells were initially treated with 0.5 nM staurosporine for 48 hours, followed by treatment with increasing concentrations of camptothecin for an additional 24 hours. The cells were then washed and incubated in drug-free medium for the 12-day recovery period. At the end of the recovery period, cytotoxicity was monitored by the MTT assay.
DNA Content Analysis
Flow cytometry was performed on normal and tumor cells after treatment with staurosporine to determine the cell cycle distribution. Briefly, medium was removed 24-36 hours after the initial plating of cells on 10-cm plates (10 6 cells per plate) and replaced with fresh medium alone or containing staurosporine as indicated for 48 hours. The cells were then harvested, and flow cytometry analysis was performed. For fluorescence-activated cell sorter analysis, 10 6 cells were centrifuged at 1000g for 5 minutes at 4°C, fixed by the gradual addition of ice-cold 70% ethanol (30 minutes at 4°C), and washed with phosphate-buffered saline (PBS). The cells were then treated with ribonuclease (10 g/mL) for 30 minutes at 37°C, washed once with PBS, resuspended, and stained in 1 mL of 69 M propidium iodide in 38 mM sodium citrate for 30 minutes at room temperature. The cell cycle distribution was determined by analytical DNA flow cytometry as described previously (18) .
Western Blot Analysis, Immunoprecipitation, and H1 Kinase Analysis
Cell lysates were prepared and analyzed on western blots as described previously (24) . Briefly, 50g of protein per lane was subjected to sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis for pRb (7% gel), for p53 (10% gel), or for p21, p27, CDK2, or CDK4 (13% gel) and transferred to a PVDF (i.e., polyvinylidene difluoride) membrane (NEN Life Sciences Products, Inc., Boston, MA) overnight at 4°C at a constant 35 mV. The blots were blocked overnight at 4°C in Blotto (i.e., 5% nonfat dry milk, 20 mM Tris-HCl [pH 7.6], 137 mM NaCl, and 0.25% Tween 20). After six 10-minute washes in TBST (i.e., 20 mM Tris-HCl [pH 7.6], 137 mM NaCl, and 0.05% Tween 20), the blots were incubated in primary antibodies for 3 hours. Primary antibodies used were a pRb monoclonal antibody (MAb) (PharMingen, San Diego, CA), MAbs to p27, CDK2, and CDK4 (Transduction Laboratories, Lexington, KY), and MAbs to p21 and p53 (Oncogene Research Products/Calbiochem, San Diego, CA); all were used at 0.1 g/mL in Blotto. The primary actin MAb (BoehringerMannheim Biochemicals, Indianapolis, IN) was used at 0.63 g/mL in Blotto. After incubation with the primary antibody, blots were washed and incubated with goat anti-mouse antibody conjugated to horseradish peroxidase (diluted 1 : 5000 in Blotto) for 1 hour and finally washed and developed with the Renaissance chemiluminescence system as directed by the manufacturer (NEN Life Sciences Products, Inc.).
For immunoprecipitation followed by western blot analysis, polyclonal antibody to CDK2 (24) or CDK4 and 300 g of cell extract were used per immunoprecipitation reaction mixture (Santa Cruz Biochemicals, Santa Cruz, CA), as described previously (25) . The immunoprecipitates were then subjected to electrophoresis in 13% gels, transferred to PVDF membrane, blocked, and incubated with the indicated antibodies as described above. For the histone H1 kinase assay, the immunoprecipitates were incubated with kinase assay buffer containing 60 M adenosine triphosphate (ATP) and 5 Ci of [ 32 P]ATP in a final volume of 50 L at 37°C for 30 minutes. Reaction products were then analyzed by SDS-polyacrylamide gel electrophoresis on a 13% gel that was then stained, destained, dried, and exposed to x-ray film.
Lymphocyte Isolation
Heparinized blood from normal donors was diluted 1 : 1 with Mg 2+ /Ca 2+ -free PBS. Peripheral blood mononuclear cells (PBMCs) were isolated by overlaying the blood-PBS mixture on 15 mL of Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) in a 50-mL conical tube and centrifuging at 1000g for 12 minutes at room temperature. The PBMC layer was removed and washed once in PBS at room temperature and twice with PBS at 4°C. The cells were suspended at 2 × 10 6 cells/mL in RPMI-1640 medium containing 2 mM L-glutamine, 0.9% NaHCO 3 , 1 mM sodium pyruvate, and 1× nonessential amino acids (BioWhittaker, Inc., Walkersville, MD). The cells were plated at various densities and stimulated with phytohemagglutinin (Sigma Chemical Co.) at a final concentration of 10 g/mL. For drug treatment followed by MTT assays, phytohemagglutinin-stimulated or unstimulated cells or cells treated with phytohemagglutinin and staurosporine were plated in 96-well plates at 10 000 cells per well and analyzed as described above for mammary epithelial cells.
Statistical Analysis
All error bars presented are 95% confidence intervals of the population mean.
RESULTS
Effectiveness of the Staurosporine Protection Strategy
We used normal proliferating, immortalized, and tumorderived mammary epithelial cell lines. Three normal proliferating cell strains, 81N, 70N, and 76N, were established from reduction mammoplasties obtained from three individuals (26) . Proliferation of these normal cell strains is strictly regulated by checkpoint controls; at the end of their lifespan, these normal cells stop proliferating and become senescent (26, 27) . We also examined a near-diploid immortalized cell line, MCF-10A, that has lost its strict growth factor requirement, its G 1 -to-S phase checkpoint regulation, and the ability to senesce (28) as well as a panel of 10 breast cancer cell lines that have different p53, pRb, and tumorigenicity statuses (27, 29) . We used a subset of these cells to examine the two criteria that are required for our hypothesis: 1) The cytostatic agent used must inhibit differentially the proliferation of normal versus tumor cells, and 2) the arrest of normal cells by the cytostatic agent must be reversible. Initially, we examined several agents with specific cell cycle targets, including olomoucine and roscovitine, two purine analogues (30, 31) , and flavopiridol, a flavone analogue (32) . All three agents specifically target CDKs. We also examined stau-rosporine, a potent protein kinase C inhibitor (33, 34) . When we measured the growth-inhibitory activity of these four agents against a panel of seven normal and tumor cell lines (Fig. 1) by the MTT assay, we found that the specific CDK inhibitors olomoucine ( Fig. 1, A) , roscovitine ( Fig. 1, B) , and flavopiridol ( Fig. 1, C) inhibited the growth of normal and tumor cells with similar potency. For these analyses, we treated the normal breast epithelial cell strains 76N and 81N, one immortalized cell line (MCF-10A), and four breast cancer cell lines (MCF-7, T47D, MDA-MB-157, and MDA-MB-436) with the indicated concentrations of the agents for 48 hours and then analyzed cell growth inhibition with the MTT assay. We observed that olomoucine, roscovitine, and flavopiridol inhibited the growth of normal and tumor cells similarly, although 81N and 76N normal cells were slightly more sensitive to the agents than all other cells examined (Fig. 1, A-C) . However, when the drug was removed, the normal cells did not recover (data not shown); thus, these agents did not meet either criterion.
Unlike CDK inhibitors, staurosporine at very low concentrations 1 could differentiate between normal and tumor cells (Fig.  1, D) . We observed that treatment of 76N and 81N normal breast epithelial cells with concentrations of staurosporine as low as 0.5 nM inhibited 40%-55% of the growth. Higher concentrations of staurosporine (i.e., 2 nM) inhibited the growth of 76N and 81N cells by up to 75%. Tumor cells, however, were not affected by these low concentrations of staurosporine. Treatment of breast cancer cell lines, such as T47D, MDA-MB-436, MDA-MB-157, and MCF-7, with concentrations as high as 8 nM staurosporine resulted in minimal or no growth inhibition (Fig. 1, D) . Thus, staurosporine inhibited the proliferation of normal cells better than the proliferation of tumor cells, unlike olomoucine, roscovitine, or flavopiridol. Thus, staurosporine meets the first criterion of the protection strategy; i.e., it inhibits proliferation of normal cells at a lower cytostatic dose than that required for cancer cells. To examine the ability of staurosporine to meet the second criterion, namely, reversibility of growth inhibition, we e., 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Percent of control was indicated for each cell line, and each data point is the average of six determinations. The assays were performed at least three times, and error bars are 95% confidence intervals, shown when larger than the corresponding symbol. E) Recovery from staurosporinemediated growth inhibition in 81N normal cells. Recovery was measured with MTT assay every day during the 48 hours of treatment and every third day after drug removal (arrow). The experiment was repeated three times, and error bars are 95% confidence intervals, shown when larger than the corresponding symbol. measured the rate of recovery of growth inhibition of the normal 81N cells treated with increasing concentrations of staurosporine (Fig. 1, E) . After 48 hours of treatment, staurosporine was removed and the cells were allowed to recover for 12 days. We observed that normal cells treated with concentrations of staurosporine up to 0.5 nM completely recovered from growth inhibition, but those treated with concentrations of staurosporine greater than 1 nM did not recover (Fig. 1, E) . Thus, staurosporine appears to be a candidate cytostatic agent that reversibly inhibits the growth of normal cells without perturbing the proliferation of tumor cells.
We next determined the cell cycle distribution of staurosporine-treated normal cells by using flow cytometry. When treated for 48 hours with 0.5 nM staurosporine, an increased number of normal cells (70N and 81N) were found in G 1 phase, a decreased number were seen in S phase, and essentially no change was observed in the number of cells in G 2 /M phases (Fig. 2) . The cell cycle distribution was not perturbed in tumor cells (i.e., MDA-MB-157 and MDA-MB-436) treated with staurosporine at concentrations up to 10 nM (Fig. 2) . These results suggest that low concentrations of staurosporine (i.e., 0.5-10 nM) inhibit the growth of normal cells mainly by inducing a reversible G 1 arrest. We then examined the cell cycle distribution of three normal mortal cell strains, i.e., 70N, 81N, and 76N, 24 hours after staurosporine treatment (i.e., after a 48-hour exposure to 0.5 nM staurosporine). We found that all three normal cell strains recovered from staurosporine-mediated G 1 arrest and returned to a normal cell cycle distribution by the end of the recovery period ( Table 1) .
Loss of Staurosporine-Mediated G 1 Arrest in Tumor Cells
To determine whether p53 or pRb was involved in staurosporine-mediated G 1 arrest, we treated 76NE6 and 76NE7 immortalized variants of 76N cells with staurosporine. These cell lines were derived from 76N cells infected with human papillomavirus 16 E6 or 16 E7 (20, 21) . The interactions between E6 and p53 promote degradation of p53 and between E7 and pRb promote inactivation of pRb, resulting in the loss of the normal phenotype (35) (36) (37) . Staurosporine treatment of 76N parental cells and 76NE6 cells resulted in the identical dose-dependent growth inhibition (data not shown) with an identical doseresponse curve (see Fig. 1 ). At only 0.5 nM staurosporine, the growth of 76NE6 cells was inhibited and the cells accumulated in G 1 phase (Fig. 2) , even though these cells had a defective p53 pathway. However, the growth of 76NE7 cells was not inhibited by staurosporine up to 10 nM, with little cell cycle perturbation (Fig. 2) 
Cell Cycle Perturbation of Normal and pRb-Defective Mammary Epithelial Cells by Staurosporine
We next identified molecular markers that are modulated in only normal cells and thus may contribute to selective staurosporine-mediated G 1 arrest. Specifically, we examined the expression and activity of regulatory molecules (pRb, p53, p21, p27, CDK2, and CDK4) associated with the progression of normal 76N and 81N cells and immortalized 76NE6 and 76NE7 cells from G 1 to S phase (Fig. 3) . Cyclin D/CDK4/CDK6 complexes primarily regulate pRb phosphorylation required for progress through G 1 phase, and cyclin E/CDK2 complexes further phosphorylate pRb from late G 1 to S phase (15, 39, 40) . p21 and p27, which inhibit many CDKs, selectively bind to and inhibit cyclin/CDK complexes and thus also inhibit pRb phosphorylation. Levels of CDK4, p53, pRb, p21, and CDK2 declined in 76N and 81N normal cell strains treated with staurosporine, and levels of p27 were unaffected (left panels of Fig. 3, A) . Levels of cyclin D3, cyclin E, and cyclin A were also reduced after staurosporine treatment (data not show). The most distinctive change in response to staurosporine was the rapid and complete disappearance of CDK4, which occurred before complete hypophosphorylation of pRb 3 and concomitantly with a decrease in CDK2 activity (left panels of Fig. 3, B) . Increased binding of p27 to CDK2, detected by immunoprecipitation, could contribute to the rapid decrease in CDK2 activity observed in normal cells (41, 42) . However, because the level of p27 was not altered by staurosporine treatment, we also examined the association of p21 and p27 with CDK4 to determine if p27 had switched partners from CDK4 to CDK2 (41, 42) . These analyses revealed that p27 binding to CDK2 increased over the staurosporine concentrations examined, with only a twofold to threefold increase in CDK2/p27 complex formation at lower staurosporine concentrations. The increase in binding of p27 to CDK2 is concomitant with the inactivation of CDK2 (due to the transfer of p27 from staurosporine-induced disappearance of CDK4; left panels of Fig. 3, B) . Cell cycle perturbations similar to those shown in Fig.  3 were also detected in normal cells treated with 0.5 nM staurosporine (data not shown).
A similar analysis was performed with 76NE6 (p53 inactive) and 76NE7 (pRb inactive) immortalized cell lines (right panels of Fig. 3, A) . After 76NE6 cells were treated with staurosporine, CDK4 levels decreased before hypophosphorylation of pRb and concomitant with inactivation of CDK2. pRb-inactive 76NE7 cells, however, were not affected by staurosporine treatment (right panels of Fig. 3, B) . Furthermore, staurosporine had no effect on the levels or activities of any cell cycle regulators examined in breast cancer cell lines (data not shown). Thus, treatment of normal proliferating mammary epithelial cells with staurosporine results in a dramatic pRb-dependent decline of CDK4. Loss of CDK4 is the first, and possibly the most crucial, step required for staurosporine-mediated G 1 arrest. CDK2 then is inactivated by the binding of p27 that was released from CDK4. These staurosporine-mediated changes are associated with the G 1 arrest in 76N and 81N normal cells and 76NE6 immortalized cells but are not observed in staurosporine-treated 76NE7 cells or tumor cells.
Pretreatment With Staurosporine of Normal Cells and Protection From the Toxic Effects of DNADamaging Agents
To examine the protection strategy, we pretreated normal 81N cells and two breast cancer cell lines, MDA-MB-436 and MDA-MB-157, with 0.5 nM staurosporine for 48 hours, which arrests normal cells in G 1 . We then treated these cells with cytotoxic concentrations of 0.125 M doxorubicin or 0.5 M camptothecin for 24 hours (Fig. 4) . The drugs were removed, and the cells were allowed to recover for 12 days. Cell proliferation was measured with the MTT assay as indicated (Fig. 4) . The staurosporine pretreatment of normal cells inhibited prolif- 70N, 81N , and 76N cells were either untreated (control) or treated with 0.5 nM ST for 48 hours or with 0.5 nM ST for 48 hours followed by a 24-hour recovery in drug-free medium. At the end of each treatment, cells were subjected to flow cytometry. The experiment was repeated five times.
†Values ‫ס‬ mean ± 95% confidence interval.
Fig. 3. Cell cycle perturbation induced by staurosporine (ST) in normal cells is retinoblastoma protein (pRb) dependent. Normal cell strains (76N and 81N), 76NE6 (p53 inactive)
, and 76NE7 (pRb inactive) were treated with ST as indicated for 48 hours. After treatment, cells were harvested and cell lysates were prepared and used for western blot analysis (A) or for analysis of cyclindependent kinase (CDK) 2 kinase activity or CDK2 and CDK4 immune-complex formation (B). For western blot analysis, 50 g of protein extract from each condition was examined with seven antibodies as indicated. Actin was used to demonstrate equal loading. The blots were developed with chemiluminescence reagents. The same blots were sequentially hybridized with different antibodies. After each antibody-binding experiment, blots were stripped with a solution of 100 mM 2-mercaptoethanol, 62.5 mM Tris-HCl (pH 6.8), and 2% sodium dodecyl sulfate (SDS) for 10 minutes at 55°C. For CDK2 kinase activity, equal amounts of cell lysate protein (300 g) from each cell line were immunoprecipitated with anti-CDK2 antibody (polyclonal) coupled to protein A beads; histone H1 was the kinase substrate. For each cell line, the resulting autoradiograph of the phosphorylated histone H1 after SDS-polyacrylamide gel electrophoresis is shown. For immunoprecipitation followed by western blot analysis, equal amounts of cell lysate protein (300 g) prepared from each cell line were immunoprecipitated with anti-CDK2 (polyclonal) or anti-CDK4 (polyclonal) coupled to protein A beads, and the immunoprecipitates were analyzed on western blot with the indicated antibodies.
eration of these cells by 30%-50% but did not affect the proliferation of breast cancer cells. After staurosporine was removed, the normal cells recovered, and their rate of proliferation and total number approached those of control untreated cells by the end of the experiment. The staurosporine-mediated arrest of normal cells protected them from the toxic effects of doxorubicin (Fig. 4, A) or camptothecin (Fig. 4, B) . In fact, pretreatment of normal cells with staurosporine resulted in a similar recovery whether or not the cells were also treated with chemotherapeutic agents, whereas the growth of non-pretreated, chemotherapytreated normal cells was inhibited and the cells had not recovered at the end of the experiment (Fig. 4) . Staurosporine did not substantially affect the proliferation of cancer cells, and staurosporine pretreatment did not alter substantially the cytotoxicity of doxorubicin or camptothecin. Thus, pretreatment with staurosporine protected normal cells from the toxic effects of doxorubicin and camptothecin, whereas tumor cells, which are insensitive to staurosporine, were killed.
Staurosporine and Maximum Tolerated Dose of Camptothecin
One of the limitations in cancer therapy is the maximum tolerated dose of a drug administered to patients that can effectively treat their cancer without causing intolerable toxicity. If the maximum tolerated dose of a chemotherapeutic agent could be increased, higher doses could be given to destroy more tumor cells without killing normal healthy cells. We propose that pretreatment with a drug, such as staurosporine, can increase the maximum tolerated dose of chemotherapeutic agents. We tested this hypothesis on the following five cell lines: two normal breast epithelial cell strains (81N and 70N) , the breast cancer cell line MDA-MB-436, and two immortalized cell lines (76NE6 and 76NE7) (Fig. 5) . All cells were treated with 0.5 nM staurosporine for 48 hours and then were treated with camptothecin as indicated for 24 hours. The drug was removed, the cells were incubated in drug-free medium for 12 days, and then cell proliferation was monitored by the MTT assay (Fig. 5) . Tumor cells, unaffected by pretreatment with staurosporine, were very sensitive to camptothecin, with an IC 50 (i.e., half-maximal toxicity) of 20 nM. Normal 81N and 70N cells that were treated with staurosporine and arrested in G 1 were protected from the toxic effects of camptothecin (IC 50 ‫ס‬ 1 M). The 76NE6 immortalized cells and normal cell strains behaved similarly and were even more refractory to camptothecin (i.e., IC 50 ‫ס‬ 3 M) after pretreatment with staurosporine. Lastly, 76NE7 cells behaved identically to tumor cells in their response to camptothecin (i.e., IC 50 ‫ס‬ 20 nM). Staurosporine pretreatment increased the IC 50 for camptothecin in normal cells by 50-fold compared with that in tumor cells and increased the IC 50 for camptothecin in 76NE6 cells by 150-fold compared with that in 76NE7 cells. Thus, staurosporine-mediated G 1 arrest appears to protect normal cells from the toxicity of chemotherapeutic agents by targeting the G 1 checkpoint regulated by the pRb pathway. Tumor or immortalized cells with a defective pRb pathway are not affected by staurosporine, cannot be protected by it, and thus are sensitive to very low concentrations of camptothecin.
Staurosporine Protection of Peripheral Blood Lymphocytes and Toxic Effects of Camptothecin
Immunosuppression, as measured in part by a reduced circulating lymphocyte count, is one of the major side effects of cancer therapy, resulting in impaired patient performance status. To determine whether pretreatment with staurosporine can protect lymphocytes against the toxic effects of chemotherapy, we tested our protection strategy by assessing its effects on phytohemagglutinin-induced human PBMC proliferation. Normally, 80% of the lymphocytes from healthy donors are in G 0 /G 1 phases and less than 2% are in S phase (Fig. 6, A) . To drive cells into S phase, we stimulated PBMCs with phytohemagglutinin so that approximately 20% of these cells were in S phase 48 hours later (Fig. 6, A) . These actively dividing lymphocytes were highly sensitive to camptothecin (IC 50 ‫ס‬ 10 nM) with a very steep dose-response curve, which was completely reversed by pretreatment with staurosporine (Fig. 6, B) . For these analyses, the lymphocytes were initially induced to proliferate with phytohemagglutinin for 48 hours in the presence or absence of increasing concentrations of staurosporine (i.e., 2, 4, and 10 nM). The cells were then treated with the indicated concentrations of camptothecin for 24 hours, and growth was monitored by the MTT assay. Camptothecin at 0.125 M killed more than 90% of the dividing lymphocytes. Cell death could be reduced to 72%, 43%, or less than 5% by pretreatment with 2 nM, 4 nM, or 10 nM staurosporine, respectively (Fig. 6, B) . Thus, pretreating PBMCs with staurosporine made treatment with camptothecin (Յ2 M) ineffective.
The above results suggest that the lymphocytes are more resistant than normal mammary epithelial cells to the protective effects of staurosporine because 10 nM staurosporine was required to fully protect lymphocytes, whereas 0.5 nM was effective in the cell lines. This difference in staurosporine sensitivity is due in part to the increased number of phytohemagglutininstimulated lymphocytes in S phase as shown by the effect of 0-10 nM staurosporine on the cell cycle of phytohemagglutininstimulated lymphocytes (Fig. 6, C) . Proliferating lymphocytes, which have two to three times more S-phase cells than cultured normal mammary epithelial cells, respond to staurosporine in a dose-response manner, in which concentrations less than 10 nM staurosporine only partially arrested the cells. Thus, the protec- tive effects and the cell cycle effects of staurosporine on phytohemagglutinin-stimulated lymphocytes (Fig. 6, B) occur at very similar concentrations (Fig. 6, C) .
Staurosporine-mediated protection of lymphocytes from camptothecin toxicity likely results from their arrest in G 1 (Fig.  7) because 10 nM staurosporine reversibly blocked (11.4%, S + G 2 /M; Fig. 7 , C) phytohemagglutinin-induced lymphocyte activation (26%, S + G 2 /M; Fig. 7, B) . The blockage by staurosporine was reversible. After staurosporine was removed at 48 hours, cultures not pretreated with staurosporine had 19% of the cells in S + G 2 /M at 96 hours (Fig. 7, E) , while the staurosporine-protected (0-48 hours) cells had 30% of the cells in S + G 2 /M (Fig. 7, F) . Thus, cells initially arrested in the cell cycle by staurosporine could progress through it when staurosporine was removed. In addition, apoptotic cell death was initiated in cells incubated continuously in phytohemagglutinin for 96 hours (i.e., 23% in sub-G 1 ; Fig. 7, E) ; however, when the cells were treated with staurosporine, fewer cells entered phytohemagglutinininduced apoptosis after 96 hours (i.e., 2% in sub-G 1 ; Fig. 7, F) . Thus, treatment of circulating lymphocytes with staurosporine protected the cells not only from camptothecin-mediated toxicity but also from phytohemagglutinin-mediated apoptotic cell death by reversibly arresting the cells in G 1 phase.
DISCUSSION
We have shown that a two-step treatment with a cytostatic agent and then conventional chemotherapy protects normal proliferating cells from the toxic effects of chemotherapeutic agents. Treatment of normal cells with a cytostatic agent reversibly arrests them in G 0 /G 1 phase and thus protects them from death induced by chemotherapeutic agents. Tumor cells with defects at the G 1 checkpoint are not arrested in G 1 phase by staurosporine, continue to proliferate, and are thus susceptible to chemotherapeutic agents.
Conventional cancer therapy targets all proliferating cells; thus, many normal healthy cells are compromised, causing various side effects to cancer patients. Our treatment strategy selectively protects normal cells that have functional, tightly regulated checkpoint controls. Tumor cells are very heterogeneous with various deregulated checkpoints (7). Our treatment strategy targets the G 1 /S transition checkpoint governed by the pRb pathway, a pathway altered in the majority of cancers (43) . Defects in the pRb pathway are caused by a variety of mechanisms, including overexpression of cyclin D or E, overexpression of CDK4 and/or CDK6, or inactivation of p16 (8, 29, 39, (44) (45) (46) (47) . In this article, we have shown that, in normal cells, low concentrations of staurosporine target this pathway under conditions where it is tightly regulated and its components are neither overexpressed nor inactivated. Specifically, we have shown that, when normal cells are treated with very low concentrations of staurosporine (i.e., 0.5-2 nM), the levels of CDK4 decrease substantially, and we propose that this decrease results in a cascade of downstream events, leading to G 0 /G 1 arrest. In normal proliferating cells, CDK4 is complexed with p27 and the kinase is active [ Fig. 3 and (25,48,49) ]. CDK4/p27 complexes increase the binding efficiency of CDK4 to cyclin D1 and sequester p27, which controls the amount of p27 available to inhibit CDK2 activity (24, 25, 48, 50) . When CDK4 levels fall, p27 is released, which allows p27 to bind to CDK2 and inhibit its activity (Fig.  3) . Hypophosphorylation of pRb and subsequent G 1 arrest follow this inhibition. The mechanism by which staurosporine decreases CDK4 levels is currently unknown; however, staurosporine mediated a decrease in CDK4 levels, a pRb-dependent primary event leading to G 1 arrest of normal cells (Fig. 3) . We also showed that, in cells transformed by the E7 gene, which targets pRb, staurosporine does not alter CDK4 levels or lead to G 0 /G 1 arrest (Figs. 2 and 3) . Similarly, staurosporine does not alter CDK4 levels in tumor cells with a deregulated pRb pathway. Our results suggest that that CDK4 may be the rate-limiting step in staurosporine-mediated G 1 arrest.
The strengths of the protection strategy are the selectivity of staurosporine in normal proliferating cells and its potential ability to be used ubiquitously with various chemotherapeutic agents in the second step of treatment. Staurosporine is more specific than many other protein kinase C or CDK inhibitors for selectively arresting normal (and not tumor) cells and is effective at very low doses (Fig. 1) . Staurosporine differentially inhibits normal and tumor cells by arresting cells in G 1 phase [ Fig. 2 and  (51,52) ], and its effects on normal lymphocytes are reversible (Figs. 6 and 7) , an issue critical to our model. Pretreatment of normal cells with staurosporine protected them against the cytotoxic effects of two chemotherapeutic agents with different modes of action. Camptothecin is a topoisomerase I inhibitor and triggers DNA degradation in S phase, whereas doxorubicin inhibits topoisomerase II, which causes double-stranded DNA breaks and induces cells to arrest in S and G 2 (53) . Because pretreatment arrested normal cells in G 0 /G 1 phase and made them quiescent, they are refractory to the toxic effects of chemotherapeutic agents. We observed that the viability of quiescent circulating lymphocytes was minimally affected by increasing concentrations of camptothecin but that the viability of proliferating lymphocytes treated similarly was substantially decreased (Fig. 6) . The effectiveness of this strategy with other chemotherapeutic agents requires further investigation; however, it is reasonable to assume that, as long as the normal proliferating cells are arrested in G 0 /G 1 by staurosporine, they should be protected from chemotherapeutic agents that target proliferating cells.
Another advantage of the protection strategy is its potential for generating an increased therapeutic index. In Fig. 5 , we showed that staurosporine pretreatment of normal cells increased the maximum tolerated dose of camptothecin by two orders of magnitude. The clinical implications of a higher therapeutic index for any given drug are that it may be possible to shorten the time course of chemotherapy, reduce the frequency of drug resistance, potentially decrease the rate of relapse, and/or increase the frequency of complete response to conventional chemotherapy.
In summary, we show that normal proliferating mammary epithelial cells or dividing lymphocytes can withstand otherwise lethal doses of chemotherapy if they are pretreated with staurosporine to arrest the cells in G 0 /G 1 phase before chemotherapy is started. Tumor cells are refractory to low concentrations of staurosporine and do not arrest in G 1 because of defective G 1 checkpoints. The G 1 checkpoint that is targeted by low concentrations of staurosporine in normal cells is regulated by the pRb pathway. Because pRb is tightly regulated in normal cells and defective in most tumors, this treatment strategy is highly specific and effective for protecting normal cells against the toxicity of chemotherapeutic agents with different modes of action.
